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disOBJECTIVES This study sought to deﬁne the prevalence and prognostic impact of blood transfusions in contemporary
percutaneous coronary intervention (PCI) practice.
BACKGROUND Although the presence of anemia is associated with adverse outcomes in patients undergoing PCI,
the optimal use of blood products in patients undergoing PCI remains controversial.
METHODS A search of EMBASE and MEDLINE was conducted to identify PCI studies that evaluated blood transfusions and
their associationwithmajor adverse cardiac events (MACE) andmortality. Two independent reviewers screened the studies for
inclusion, and data were extracted from relevant studies. Random effects meta-analysis was used to estimate the risk of
adverse outcomes with blood transfusions. Statistical heterogeneity was assessed by considering the I2 statistic.
RESULTS Nineteen studies that included 2,258,711 patients with more than 54,000 transfusion events were identiﬁed
(prevalence of blood transfusion 2.3%). Crude mortality rate was 6,435 of 50,979 (12.6%, 8 studies) in patients who
received a blood transfusion and 27,061 of 2,266,111 (1.2%, 8 studies) in the remaining patients. Crude MACE rates were
17.4% (8,439 of 48,518) in patients who had a blood transfusion and 3.1% (68,062 of 2,212,730) in the remaining cohort.
Meta-analysis demonstrated that blood transfusion was independently associated with an increase in mortality (odds ratio:
3.02, 95% conﬁdence interval: 2.16 to 4.21, I2 ¼ 91%) and MACE (odds ratio: 3.15, 95% conﬁdence interval: 2.59 to 3.82,
I2 ¼ 81%). Similar observations were recorded in studies that adjusted for baseline hematocrit, anemia, and bleeding.
CONCLUSIONS Blood transfusion is independently associated with increased risk of mortality and MACE events.
Clinicians should minimize the risk for periprocedural transfusion by using available bleeding-avoidance strategies
and avoiding liberal transfusion practices. (J Am Coll Cardiol Intv 2015;8:436–46) © 2015 by the American College of
Cardiology Foundation.A dvances in antiplatelet and antithrombotictherapy have improved outcomes in patientsundergoing percutaneous coronary interven-
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437following major bleeding events, with previous
studies reporting marked variation in the use of red
blood cell transfusion among patients with acute cor-
onary syndromes (6) and in patients undergoing PCI
(5). Whereas the presence of anemia is independently
associated with an increase in cardiac mortality and
myocardial infarction in patients with acute coronary
syndromes or undergoing PCI (7,8), the optimal use of
blood products in such patients remains controver-
sial. National transfusion practice guidelines offer
no recommendation for or against a liberal or restric-
tive transfusion threshold for such patients (9). Na-
tional PCI registries have demonstrated that patients
with bleeding events receive blood transfusions
across the spectrum of hemoglobin values with signif-
icant variation in practice (5), and a single-center
study showed that a large proportion of patients un-
dergoing PCI received transfusion for indications
outside of published guidelines (10).SEE PAGE 447A previous meta-analysis of 10 studies including
203,665 patients reported that blood transfusion
in the setting of acute myocardial infarction is
associated with a 3-fold increase in all-cause mor-
tality and a 2-fold increase in recurrent myocardial
infarction (11), although it included studies mainly
of patients with acute coronary syndromes who
did not undergo PCI and were managed medically,
hence the applicability of the ﬁndings to patients
undergoing PCI remains unclear. Deﬁning the role of
transfusion in patients undergoing PCI can inform
clinical practice. There has not been a systematic
review or meta-analysis of the prevalence and
prognostic impact of blood transfusion in the setting
of PCI. We have therefore undertaken a meta-
analysis to systematically study the impact of
blood transfusion in patients who have undergone
PCI on mortality and MACE outcomes. In this meta-
analysis, we provide an overview of the cohorts,
evaluating the rates of blood transfusion events and
systematically studying the differences in the prog-
nostic impact of blood transfusion in patients un-
dergoing PCI.
METHODS
ELIGIBILITY CRITERIA. Studies were selected of pa-
tients who underwent PCI reporting mortality or
cardiovascular events among patients with and
without blood transfusion with no restriction based
on study design or the indication for PCI. Studies that
did not report on transfusion and those that did not
report either mortality or MACE were excluded.SEARCH STRATEGY. A search of EMBASE
(1974 to March 4, 2014) and MEDLINE (1946
to March 4, 2014) was conducted on OVID SP.
We used the following search terms: (trans-
fusion AND (percutaneous coronary inter-
vention OR PCI) AND mortality). Studies in all
languages and both abstracts and unpub-
lished studies were included. The bibliogra-
phies of the included studies and relevant
review articles were checked for additional
relevant articles. Authors were contacted in situa-
tions in which there was uncertainty regarding the
data in the studies.
STUDY SELECTION AND DATA EXTRACTION. Two
reviewers (C.S.K. and S.W. or S.N.) independently
checked all titles and abstracts for studies potentially
meeting the inclusion criteria. The full reports of
these studies were retrieved, and data were inde-
pendently extracted on study design, participant
characteristics, interventions used, type of trans-
fusions, outcome events, and follow-up. Any dis-
crepancies between the 2 reviewers were resolved by
consensus after consulting a third reviewer (M.A.M.).
QUALITY ASSESSMENT. Risk of bias was assessed by
considering ascertainment of transfusion, ascertain-
ment of outcomes, baseline differences between the
transfused and not transfused group, loss to follow-
up, and use of adjustment in data analysis. Publica-
tion bias was assessed using funnel plots when there
were >10 studies available in the meta-analysis and
there was no evidence of substantial statistical het-
erogeneity (12).
DATA ANALYSIS. The program RevMan (version 5.1.7,
Nordic Cochrane Centre, Copenhagen, Denmark) was
used to do random effects meta-analysis using the
inverse variance method for pooled odds ratios.
Similarity was assumed between the odds ratio
and other relative measures such as relative risk,
rate ratios, or hazard ratios (HRs) because cardiovas-
cular events and death were rare events (13). Adjusted
or propensity-matched risk estimates were used
where available. For datasets reporting multiple time-
points, the earliest time point was included in the
primary analysis. The I2 statistic was used to assess
statistical heterogeneity.
Several analyses were undertaken. The primary
analysis was the risk of mortality and MACE with and
without transfusion. In addition, further analysis
considering adverse outcomes at a longer follow-up
duration were undertaken. Additional analyses
were performed to evaluate the risk of death consid-
ering anemia, the inﬂuence of number of units
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438transfused, the transfusion volume, the red blood cell
storage age, use of platelet transfusion, and use of
plasma/cryoprecipitate. There was no strict deﬁnition
of anemia.
RESULTS
STUDY SELECTION. Study selection is shown in
Figure 1. We retrieved 19 relevant studies of patients
who underwent PCI (2,5,14–30) (total number of
subjects 2,381,623 in 16 studies (2,5,14,16–26,29,30),
3 studies examined different types of transfusions
in the same cohort (15,27,28), 54,380 transfused,
2,327,243 not transfused), which evaluated the risk of
adverse events with and without blood transfusion.
The number of participants in each study ranged from
1973 (26) to 2,258,711 (5), and the prevalence of blood
transfusion varied from 1.6% (25) to 22% (20).
DESCRIPTION OF STUDIES INCLUDED. The study
designs, date of study, country of origin, and indica-
tion for PCI are shown in Table 1. There were 3 that
were post-hoc analyses of randomized controlled
trials, 6 prospective cohort studies, 4 retrospective
cohort studies, 5 cohort studies, and 1 case-control
study. There were more multicenter studies than
single-center studies (n ¼ 10 and n ¼ 6). The age,
sex, comorbidities, and treatments are shown in
Online Table 1.
Table 2 provides an overview of the PCI cohort,
type of transfusion, and outcomes for each studyFIGURE 1 Flow Diagram of Study Selection
From 476 studies identiﬁed from the initial search, a total of 19 studies w
of potentially relevant studies. PCI ¼ percutaneous coronary interventioincluded in the meta-analysis. All studies evaluated
red blood cell transfusion, and 1 study also evaluated
platelet transfusion and use of plasma or cryopreci-
pitate. Fifteen studies assessed transfusion and risk
of death, and 5 studies assessed transfusion and
risk of MACE. In addition, 1 study considered
anemic and non-anemic (pre-PCI anemia deﬁned as
hemoglobin <13 g/dl in male and <12 g/dl in female)
subgroups (17), and 2 studies evaluated the number of
units of blood transfused (18,28). Follow-up of pa-
tients varied from in-hospital outcomes up to 5 years.
QUALITY ASSESSMENT. Online Table 2 shows the
quality assessment for included studies. Ascertain-
ment of transfusion and outcomes varied from med-
ical record reviews to prospective evaluation in trials
with adjudicated bleeding and outcome events. There
were baseline differences in the transfusion and
non-transfused group in 14 studies (74%), and 8
studies (42%) reported some degree of loss to follow-
up. All studies included in this meta-analysis used
adjustment or propensity matching.
TRANSFUSION AND RISK OF MORTALITY AT ANY
TIME POINT. The impact of transfusion on mortality
outcomes was considered in 19 studies, reporting
outcomes in 2,419,969 patients (2,5,14–30). As sum-
marized in Table 2, 54,380 participants with trans-
fusions were reported. Mortality rate was 6,435 of
50,979 (13%, 8 studies (2,5,19–21,26,29,30), as not all
studies report crude rate of events) in patients who
received a blood transfusion and 27,061 of 2,266,111ere included after screening titles and reviewing the full manuscripts
n.
TABLE 1 Study Design, Location, and Participant Inclusion Criteria
Year Design Date of Study Centers, n Country Participant Inclusion Criteria
Brugts et al. (14) 2009 Post-hoc analysis of randomized
control trial (EXCITE trial)
June 1997 to April 1998 412 International Participants had angiographic evidence of clinically signiﬁcant
coronary artery disease necessitating percutaneous
transluminal coronary revascularization.
Byrne et al. (15) 2009 Prospective cohort study (British
Columbia Cardiac Registry)
January 1999 to December 2005 4 Canada Participants had PCI.
Chase et al. (2)
(Same cohort as
Byrne et al.)
2008 Prospective cohort study (British
Columbia Cardiac Registry)
January 1999 to December 2005 4 Canada Participants had PCI.
Cosgrove et al. (16) 2009 Retrospective cohort study (MIDAS) 2003 to 2004 Multiple USA Participants had PCI and STEMI.
Dada et al. (17) 2009 Cohort study Unclear Unclear USA Participants had PCI.
Doyle et al. (18) 2008 Cohort study (Mayo Clinic) 1994 to June 2005 1 USA Participants had transfemoral PCI.
Ergelen et al. (19) 2012 Retrospective cohort study October 2003 to March 2008 1 Turkey Participants had PCI and STEMI.
Jani et al. (20) 2007 Prospective cohort study (BMC2) June 1997 to January 2004 Multiple USA Participants had PCI.
Jolicoeur et al. (21) 2009 Post-hoc analysis of randomized
control trial (APEX-AMI trial)
2004 to 2006 296 International Participants had PCI and STEMI.
Kim et al. (22) 2007 Cohort and case-control study January 2000 to April 2002 1 USA Participants had PCI.
Kinnaird et al. (23) 2003 Retrospective cohort study 1991 to 2000 1 USA Participants had PCI.
Leung et al. (24) 2010 Prospective cohort study
(Dartmouth Dynamic Registry)
July 1998 to July 2006 1 USA Participants had cardiac catheterization.
Maluenda et al. (25) 2009 Cohort study Unclear Unclear USA Participants had PCI.
Nikolsky et al. (26) 2009 Post-hoc analysis of randomized
control trial (CADILLAC trial)
November 1997 to December 1999 Multiple International Participants had acute myocardial infarction and primary PCI.
Robinson et al. (27)
(Same cohort as
Byrne et al.)
2010 Prospective cohort study (British
Columbia Cardiac Registry)
January 1999 to December 2005 4 Canada Participants had PCI.
Robinson et al. (28)
(Same cohort as
Byrne et al.)
2012 Prospective cohort study (British
Columbia Cardiac Registry)
January 1999 to December 2005 4 Canada Participants had PCI.
Sherwood et al. (5) 2014 Retrospective cohort study
(CathPCI Registry)
July 2009 to March 2013 1,400 USA Participants had cardiac catheterization or PCI.
Tajstra et al. (29) 2013 Cohort study January 1999 to December 2004 1 Poland Participants with STEMI who underwent immediate
coronary intervention.
Valenti et al. (30) 2010 Cohort study 1995 to 2007 Unclear Italy Participants had primary PCI for acute myocardial infarction.
APEX-AMI ¼ Assessment of Pexelizumab in Acute Myocardial Infarction; BMC2 ¼ Blue Cross Blue Shield of Michigan Cardiovascular Consortium; CADILLAC ¼ Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications; EXCITE ¼ Evaluation
of Oral Xemiloﬁban in Controlling Thrombotic Events; MIDAS ¼ Myocardial Infarction Data Acquisition System; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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TABLE 2 Participants, Types of Transfusions, and Outcomes
Year Cohort
Type of
Transfusion Outcomes and Follow-Up
No. of Events/Total
Participants
Transfused
No. of Events/Total
Participants Not
Transfused Results
Brugts et al. (14) 2009 PCI RBC Death and death/MI/
stroke at 7 months
Total: 189 Total: 6,506 Death: aHR 4.54 (2.48–8.33)
Composite: aHR 2.61 (1.96–3.60)
Byrne et al. (15) 2009 PCI RBC Adverse outcome at
unclear follow-up
Total: 38,346 NA Adverse outcome: aHR 2.86 (2.52–3.25)
Chase et al. (2)
(Same cohort as
Byrne et al.)
2008 PCI RBC Death at 30 days and 1 yr Death at 30 days:
122/967
Death at 1 yr:
221/967
Death at 30 days:
476/37,905
Death at 1 yr:
1,216/37,905
Death at 30 days: aOR 4.01 (3.08–5.22), propensity
matched RR 3.9 (1.89–8.0)
Death at 1 yr: aOR 3.58 (2.94–4.36), propensity
matched RR 3.38 (2.22–5.14)
Cosgrove et al. (16) 2009 STEMI and PCI RBC Death at 3 yrs Total: 207 Total: 5,381 Death at 3 yrs: aHR 1.36 (1.03–1.83)
Dada et al. (17) 2009 PCI RBC Death in-hospital and
9 months
Total: 291 Total: 6,247 Death in-hospital: anemic: OR 2.74 (1.10–6.82),
non-anemic: OR 0.48 (0.01–23.02).
Death at 9 months: anemic: OR 3.01 (1.71–5.32),
non-anemic: OR 0.06 (0.003–1.35)
Doyle et al. (18) 2008 PCI RBC Death at 30 days Total: 1,205 Total: 16,696 Death at 30 days: 3þ U: aHR 18.1 (13.7–24.0), 1–2 U:
aHR 8.9 (6.3–12.6)
Ergelen et al. (19) 2012 STEMI with PCI RBC Death and MACE (CV
death, reinfarction,
TVR) in-hospital and
at 21 months
Death in-hospital:
9/88
MACE in-hospital:
21/88
Death in-hospital
67/2,449
MACE in-hospital
155/2,449
CV death in-hospital: OR 8.1 (1.8–35.7)
MACE in-hospital: 21/88 vs. 155/2,449
Death at 21 months: 11/88 vs. 119/2,449
MACE at 21 months: 31/88 vs. 571/2,449
Jani et al. (20) 2007 Any (STEMI and
NSTEMI with PCI)
RBC Death in-hospital 150/1,033 108/3,590 Death in-hospital: aOR 2.02 (1.47–2.79)
Jolicoeur et al. (21) 2009 STEMI with PCI RBC Death at 3 months 53/204 203/4,984 Death at 3 months: aHR 2.16 (1.20–3.88)
Kim et al. (22) 2007 PCI RBC Death in-hospital and at
1 yr
Total: 146 Total: 292 Death in-hospital: OR 2.03 (1.00–3.83)
Death at 1 yr: OR 2.42 (1.32–4.46)
Kinnaird et al. (23) 2003 PCI RBC Death in-hospital and at
1 yr
Total: 593 Total: 10,381 Death in-hospital: OR 2.0 (1.1–3.2)
Death at 1 yr: OR 1.9 (1.4–2.5)
Leung et al. (24) 2010 PCI (cardiac
catheterization)
RBC Death at 30 days and long
term
Total: 709 Total: 11,952 Death at 30 days: aOR 2.22 (1.57–3.14)
Long-term mortality: aOR 1.41 (1.19–1.67)
Maluenda et al. (25) 2009 PCI RBC Death/MI at 1 yr Total: 61 Total: 3,677 Composite at 1 yr: aHR 1.93 (0.81–4.17)
Nikolsky et al. (26) 2009 Any (STEMI and
NSTEMI with PCI)
RBC Death at 1 and 12 months 11/82 87/1,891 Death at 30 days: HR 4.71 (1.97–11.26)
Death at 1 yr: HR 3.16 (1.66–6.03)
Robinson et al. (27)
(Same cohort as
Byrne et al.)
2010 PCI RBC Death at 1 month Total: 909 Total: 31,671 Death at 30 days: RBC transfusion volume:
HR 1.28 (1.19–1.38), mean RBC storage age:
HR 1.03 (1.02–1.05)
Robinson et al. (28)
(Same cohort as
Byrne et al.)
2012 PCI RBC, platelet,
and plasma/
cryoprecipitate
Death at 1 month Total: 32,580 NA Death at 30 days: RBC transfusion 1–2 U: HR 4.49
(3.21–6.28), >2 U: HR 6.33 (4.37–9.18), platelet
transfusion: HR 3.92 (2.52–6.11), plasma/
cryoprecipitate transfusion: HR 3.92 (2.52–6.11)
Continued on the next page
K
w
ok
et
al.
J
A
C
C
:
C
A
R
D
IO
V
A
S
C
U
L
A
R
IN
T
E
R
V
E
N
T
IO
N
S
V
O
L
.
8
,
N
O
.
3
,
2
0
1
5
Transfusion
A
fter
PCI
and
R
isk
of
A
dverse
O
utcom
es
M
A
R
C
H
2
0
15
:4
3
6
–
4
6
440
T
A
B
L
E
2
Co
nt
in
ue
d
Y
ea
r
Co
ho
rt
Ty
pe
of
Tr
an
sf
us
io
n
O
ut
co
m
es
an
d
Fo
ll
ow
-U
p
N
o.
of
Ev
en
ts
/T
ot
al
P
ar
ti
ci
pa
nt
s
Tr
an
sf
us
ed
N
o.
of
Ev
en
ts
/T
ot
al
P
ar
ti
ci
pa
nt
s
N
ot
Tr
an
sf
us
ed
R
es
ul
ts
Sh
er
w
oo
d
et
al
.
(5
)
20
14
PC
I
R
B
C
D
ea
th
in
-h
os
pi
ta
l
an
d
M
A
CE
D
ea
th
in
-h
os
pi
ta
l:
6
,0
52
/4
8
,4
30
M
A
CE
:
8
,4
18
/4
8
,4
30
D
ea
th
in
-h
os
pi
ta
l:
25
,8
33
/2
,2
10
,2
8
1
M
A
CE
:
6
7,
9
0
7/
2,
21
0
,2
8
1
O
ve
ra
ll
in
-h
os
pi
ta
l
m
or
ta
lit
y:
O
R
4.
6
3
(4
.5
7–
4.
6
9
)
O
ve
ra
ll
M
A
CE
:
O
R
3.
6
2
(3
.5
9
–
3.
6
6
)
W
it
h
bl
ee
d
in
-h
os
pi
ta
l
m
or
ta
lit
y:
O
R
1.
0
7
(1
.0
1–
1.
13
)
W
it
h
bl
ee
d
M
A
CE
:
O
R
1.
16
(1
.1
1–
1.
22
)
W
it
ho
ut
bl
ee
d
in
-h
os
pi
ta
l
m
or
ta
lit
y:
O
R
4.
9
6
(4
.8
9
–
5.
0
3)
W
it
ho
ut
bl
ee
d
M
A
CE
:
O
R
3.
6
6
(3
.6
3–
3.
6
9
)
Ta
js
tr
a
et
al
.
(2
9
)
20
13
ST
EM
Iw
it
h
PC
I
R
B
C
D
ea
th
at
5
yr
s
13
/8
2
9
8
/2
,3
33
D
ea
th
in
-h
os
pi
ta
l
ra
te
:
15
.8
%
vs
.
4.
2%
D
ea
th
at
30
da
ys
:
H
R
3.
1
(1
.4
1–
6
.8
)
D
ea
th
at
1
yr
:
H
R
2.
33
(1
.3
0
–
4.
17
)
D
ea
th
at
5
yr
:
ra
te
42
.7
%
vs
.
19
%
,H
R
1.
45
(1
.0
–
2.
1)
V
al
en
ti
et
al
.
(3
0
)
20
10
PC
I
R
B
C
D
ea
th
at
6
m
on
th
s
25
/9
3
18
9
/2
,6
78
Ca
rd
ia
c
de
at
h:
H
R
2.
33
(1
.4
9
–
3.
6
4)
O
R
s
an
d
H
Rs
ar
e
fo
llo
w
ed
by
(9
5%
CI
).
aH
R
¼
ad
ju
st
ed
ha
za
rd
ra
ti
o;
aO
R
¼
ad
ju
st
ed
od
ds
ra
ti
o;
CI
¼
co
nﬁ
de
nc
e
in
te
rv
al
;
CV
¼
ca
rd
io
va
sc
ul
ar
;
H
R
¼
ha
za
rd
ra
ti
o;
M
A
CE
¼
m
aj
or
ad
ve
rs
e
ca
rd
ia
c
ev
en
ts
;
M
I
¼
m
yo
ca
rd
ia
l
in
fa
rc
ti
on
;
N
A
¼
no
t
av
ai
la
bl
e;
N
ST
EM
I¼
no
n–
ST
-s
eg
m
en
t
el
ev
at
io
n
m
yo
ca
rd
ia
l
in
fa
rc
ti
on
;
O
R
¼
od
ds
ra
ti
o;
PC
I
¼
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
ti
on
;
R
B
C
¼
re
d
bl
oo
d
ce
lls
;
R
R
¼
ris
k
ra
ti
o;
ST
EM
I¼
ST
-s
eg
m
en
t
el
ev
at
io
n
m
yo
ca
rd
ia
l
in
fa
rc
ti
on
;
TV
R
¼
ta
rg
et
ve
ss
el
re
va
sc
ul
ar
iz
at
io
n;
U
¼
un
it
s.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 3 , 2 0 1 5 Kwok et al.
M A R C H 2 0 1 5 : 4 3 6 – 4 6 Transfusion After PCI and Risk of Adverse Outcomes
441(1%, 8 studies (2,5,19–21,26,29,30) in the remaining
patients.
Meta-analysis of these data demonstrated that the
overall risk of mortality was signiﬁcantly greater
among patients who had a blood transfusion (odds
ratio [OR]: 3.02, 95% conﬁdence interval [CI]: 2.16 to
4.21, I2 ¼ 91%, 15 studies) (2,5,14,16–24,26,29,30)
(Figure 2A).
TRANSFUSION AND RISK OF MACE. The impact of
transfusion on MACE was assessed in 5 studies
(5,14,15,19,25) with 2,310,047 patients. Crude rates or
risk estimates for MACE in individual studies are
shown in Table 2; 48,768 patients who received a
transfusion (2%) were included. MACE rates were 17%
(8,439 of 48,518) in patients who had a blood trans-
fusion and 3% (68,062 of 2,212,730) in patients who
did not have blood transfusion. The risk of MACE
was signiﬁcantly higher among patients with blood
transfusion (OR: 3.15, 95% CI: 2.59 to 3.82, I2 ¼ 81%)
(Figure 2B). Transfusion and the risk of adverse
outcomes at >1-year follow-up is shown in Figure 2C.
The risk of adverse outcomes in patients with >1-year
follow-up remained increased (OR: 2.06, 95% CI: 1.61
to 2.64, 9 studies) (2,16,19,22–26,29).
ADJUSTMENT FOR BASELINE ANEMIA, HEMATOCRIT,
AND BLEEDING. Meta-analysis of studies that adjusted
for baseline anemia, hematocrit, or major bleeding
are presented in Table 3. Even after adjustment for
baseline anemia, hematocrit, or bleeding events
at baseline, receipt of a blood transfusion was con-
sistently associated with a signiﬁcant 2-fold increase
in both mortality and MACE complications.
ANEMIA AND TRANSFUSION UNITS, TRANSFUSION,
AND DEATH. One study evaluated the inﬂuence of
anemia in patients who received a blood transfusion
and demonstrated that risk of mortality was signiﬁ-
cantly higher in the anemic group (anemic OR: 2.74,
95% CI: 1.10 to 6.82) compared with the non-anemic
cohort (OR: 0.48, 95% CI: 0.01 to 23.03) (Table 4) (17).
The effect of number of units transfused is consid-
ered in Table 4. Mortality risk increases with the
number of units transfused (1 to 2 units [OR: 6.31,
95% CI: 3.23 to 12.34, I2 ¼ 87%] and 3 or more units
[OR: 10.78, 95% CI: 3.85 to 30.19, I2 ¼ 95%])
(Figure 2D) (18,28).
SENSITIVITY ANALYSIS. The results of the sensi-
tivity analysis are displayed in Table 4. Signiﬁcant
differences were found for risk of death with higher
transfusion volume (HR: 1.28, 95% CI: 1.19 to 1.38),
red blood cell storage age (HR: 1.03, 95% CI: 1.02 to
1.05), platelet transfusion (HR: 3.92, 95% CI: 2.52 to
6.11), plasma/cryoprecipitate transfusion (HR: 3.92,
FIGURE 2 Risk of Adverse Outcomes With Blood Transfusion
Meta-analysis of the risk of mortality, major adverse cardiac events (MACE), and the risk of adverse outcomes at 1 year or more associated with blood transfusions and
the risk of mortality with the number of units of blood transfused. CI ¼ conﬁdence interval; IV ¼ intravenous.
Kwok et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 3 , 2 0 1 5
Transfusion After PCI and Risk of Adverse Outcomes M A R C H 2 0 1 5 : 4 3 6 – 4 6
44295% CI: 2.52 to 6.11), and death among patient with
bleeds and no bleeds (27).
PUBLICATION BIAS. Publication bias was not
assessed because there was only 1 analysis with more
than 10 studies, and there was evidence of substantial
statistical heterogeneity.
DISCUSSION
The optimal use of blood products in patients un-
dergoing PCI remains controversial. To the best of our
knowledge, the present analysis is the ﬁrst to sys-
tematically review blood transfusion and its use in
contemporary PCI practice and to study its prognostic
impact. Our meta-analysis of 19 studies including
more than 2 million patients with more than 54,000transfusion events has shown that the mean preva-
lence of blood transfusions in contemporary PCI is
2.3% and is independently associated with a 3-fold
increased risk of mortality and MACE events.
Furthermore, our data suggest a dose-dependent
adverse inﬂuence on mortality.
Both our current analysis and previous reports of
transfusion practice nationally (5) have reported a
wide variation in the prevalence of blood transfusions
in patients undergoing PCI. Whereas part of this
variation may be explained by differences in patient
characteristics and clinical settings, a recent analysis
of the National Cardiovascular Data Registry dataset
has reported signiﬁcant variations in the prevalence
of transfusion events in hospitals across the United
States, with signiﬁcant differences in hemoglobin
TABLE 3 Adjustments for Baseline Hematocrit, Anemia, and Bleeding
Studies Included Outcome Evaluated Pooled Risk Estimate
Studies that adjusted for baseline/nadir anemia (16,19,20,26,29) Risk of death 2.47 (1.53–3.97), I2 ¼ 72%, p < 0.001
Studies that adjusted for baseline/nadir hematocrit (22,24) Risk of death 2.18 (1.60–2.96), I2 ¼ 0%, p < 0.001
Studies that adjusted for bleeding (22,24,29) Risk of death 2.28 (1.71–3.04), I2 ¼ 0%, p < 0.001
Propensity matched studies (17) Risk of death 2.50 (1.03–6.07)
Studies that adjusted for baseline/nadir anemia (19) Risk of MACE 4.64 (2.77–7.77)
Studies that adjusted for baseline/nadir anemia (16,19,26,29) Risk of MACE at 1 yr or more 2.16 (1.37–3.40), I2 ¼ 67%, p < 0.001
Studies that adjusted for baseline/nadir hematocrit (22,24) Risk of MACE at 1 yr or more 1.70 (1.03–2.82), I2 ¼ 64%, p ¼ 0.04
Studies that adjusted for bleeding (22,24,29) Risk of MACE at 1 yr or more 1.83 (1.22–2.75), I2 ¼ 60%, p ¼ 0.004
Values are OR (95% CI).
Abbreviations as in Table 2.
TABLE 4 Summary of All Results
Number of Studies
(Studies Included) Risk of Adverse Outcomes
Transfusion and death 15 (2,5,14–30) OR 3.02 (2.16–4.21), I2 ¼ 91%
Transfusion and MACE 5 (5,14,15,19,25) OR 3.15 (2.59–3.82), I2 ¼ 81%
Transfusion and adverse outcome
with 1-yr or longer follow-up
9 (2,16,19,22–26,29) OR 2.06 (1.61–2.64), I2 ¼ 69%
Anemia and transfusion and death 1 (17) Anemic: OR 2.74 (1.10–6.82)
Non-anemic: OR 0.48 (0.01–23.03)
Transfusion units and
adverse outcomes
2 (18,28) 1 to 2 U: OR 6.31 (3.23–12.34),
I2 ¼ 87%
3þ U: OR 10.78 (3.85–30.19),
I2 ¼ 95%
Transfusion volume and death 1 (27) HR 1.28 (1.19–1.38)
RBC storage age and death 1 (27) HR 1.03 (1.02–1.05)
Platelet transfusion and death 1 (28) HR 3.92 (2.52–6.11)
Plasma/cryoprecipitate
transfusion and death
1 (28) HR 3.92 (2.52–6.11)
Transfusion and bleed and death 1 (5) OR 1.07 (1.01–1.13)
Transfusion and no bleed and death 1 (5) OR 4.96 (4.89–5.03)
ORs and HRs are followed by (95% CI).
Abbreviations as in Table 2.
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443threshold that prompts transfusion (5). Furthermore,
previous studies have documented that a signiﬁcant
proportion of patients receive blood transfusions in
the absence of bleeding events (5,21,26). Previous
studies in the critical care setting have reported sig-
niﬁcant institutional variation in critical care trans-
fusion practice that was independent of baseline
clinical characteristics and baseline hemoglobin con-
centration (31), reﬂecting the lack of clarity in
contemporary guidelines recommendations (9). A
recent review of blood transfusion practices reported
that variability in practices may be the result of
insufﬁcient understanding of published guidelines
and different recommendations of medical societies
(32). The prevalence of anemia in patients undergoing
PCI is signiﬁcant, with anemia documented in 23% of
patients undergoing elective or urgent PCI in the
REPLACE-2 (Randomized Evaluation of PCI Linking
Angiomax to Reduced Clinical Events) trial (33) and
between 20% and 30% in other registries (7,34,35),
with optimal hemoglobin threshold for transfusion
not clearly deﬁned.
Patients who receive blood transfusions are
generally older, more likely to be female, have more
comorbidities (5,20,21,26,27,29) and hemodynamic
compromise (21,23), and hence are more likely to have
a higher mortality. Nevertheless, even after account-
ing for these confounders, the studies included in this
meta-analysis demonstrated that blood transfusion
was an independent predictor of mortality.
The provision of blood transfusions in PCI may
relate to an acute bleeding event or occur in the
context of chronic anemia. It is therefore possible
that the relationship observed between blood trans-
fusion and adverse outcomes may be a surrogate
marker for periprocedural bleeding complications,
which we have shown in a previous meta-analysis (1)
to independently predict mortality (OR: 3.31, 95% CI:
2.86 to 3.82) and MACE (OR: 3.89, 95% CI 3.26 to
4.64). In the study of Kinnaird et al. (23) theprovision of a blood transfusion was associated with
increased in-hospital mortality in patients undergo-
ing PCI with both major bleeding events (10.6% if
transfused vs. 5.1% if not transfused) and in those
without major bleeding (10.3% vs. 0.4%) (23). Simi-
larly, in the study of Sherwood (5), patients who
were transfused and did not experience a bleed had a
greater increased risk of mortality (OR: 4.96, 95% CI:
4.89 to 5.03) than did those patients who were
transfused in the context of a bleeding complication
(OR: 1.07, 95% CI: 1.01 to 1.13). The prognostic impact
of blood transfusion is inﬂuenced by pre-procedural
anemia, and in the study by Sherwood (5), the in-
ﬂuence of blood transfusion on myocardial infarc-
tion, stroke, or in-hospital death was less in patients
with a pre-procedure hemoglobin level of <10 g/dl
(OR: 1.56, 95% CI: 1.51 to 1.62) than in those whose
hemoglobin was >15 g/dl (OR: 8.12, 95% CI: 7.96 to
8.29). We have attempted to separate the prognostic
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444impact of blood transfusion from bleeding and
baseline anemia and hematocrit by undertaking
additional analyses. A number of studies analyzed in
this meta-analysis adjusted for baseline bleeding
complications (22,24,29), and meta-analysis of these
studies revealed that receipt of a blood transfusion
was associated with a signiﬁcant increased risk of
mortality (OR: 2.28, 95% CI: 1.71 to 3.04, I2 ¼ 0%,
p < 0.001). Furthermore, adjustment for either
baseline hematocrit or anemia did not alter the
relationship between receipt of a blood transfusion
and increased risk of mortality or MACE outcomes
(Table 3). It appears that blood transfusion has an
adverse prognostic impact irrespective of whether
this has been given in the setting of a bleeding
complication and is independent to the degree of
baseline anemia or hematocrit nadir, although its
greatest prognostic value appears to be in those pa-
tients without a bleeding event.
Differences in blood transfusion practice may have
an impact on outcomes; in the CRIT (Conservative
Versus Liberal Red Cell Transfusion in Acute
Myocardial Infarction) randomized pilot trial, 45 pa-
tients with myocardial infarction and a hematocrit
level #30% were randomized to either a liberal
transfusion arm or a conservative arm, and the com-
posite endpoint of in-hospital death, recurrent
myocardial infarction, or congestive heart failure was
signiﬁcantly higher among patients assigned to the
liberal arm (38% vs. 13%; p ¼ 0.046). In contrast, in
the MINT (A Multicenter, Randomized Study of
Argatroban Versus heparin as Adjunct to Tissue
Plasminogen Activator [TPA] in Acute Myocardial
Infarction: Myocardial Infarction With Novastan
and TPA) pilot study undertaken in 110 patients pre-
senting with an acute coronary syndromes or stable
angina with anemia undergoing cardiac catheteriza-
tion, patients randomized to a liberal blood trans-
fusion strategy had one-half the primary outcome
rate of death, myocardial infarction, and unscheduled
revascularization (10.9%) as did those patients ran-
domized to a restrictive transfusion strategy (25.5%),
with lower 30-day mortality (1.8%) compared with
restrictive transfusion patients (13.0%) (p ¼ 0.032)
(36). These pilot trials support the need for a larger
National Heart, Lung, and Blood Institute–sponsored
deﬁnitive trial.
The pathophysiological mechanisms linking trans-
fusion and adverse outcomes are likely to be multi-
factorial (37). Patients receiving blood transfusions
exhibit increased platelet reactivity (38), possibly
through activation of the P2Y12 platelet receptor or
within the adenosine diphosphate pathway by
agonist or mediators contained in red blood cellpacks, placing patients at high risk of ischemic
events. Blood transfusions also increase procoagulant
proteins such as plasminogen activator inhibitor
protein (39), an inhibitor of physiological processes
that promote the degradation of thrombus. The
oxygenating capability of transfused blood may
also be impaired through a reduction in 2,3-
diphosphoglyceric acid levels in stored red blood
cells, which increases the afﬁnity of hemoglobin for
oxygen, thereby decreasing the release of oxygen to
the tissues (40), but also through mechanisms of
impaired small vessel vasodilation by a reduction in
the nitric oxide transport by red transfused blood
cells, impairing increases in the regional blood ﬂow in
zones of hypoxia (41). Finally, during storage, sig-
niﬁcant changes in the deformability of red blood
cells, as well as changes in their shape, may predis-
pose to “plugging” of transfused cells at the micro-
vascular level, leading to tissue ischemia (37).
STUDY LIMITATIONS. Whereas our meta-analysis
suggests an association between transfusion and
mortality outcomes, it cannot confer a causal rela-
tionship. Also, the provision of blood transfusions in
the setting of PCI may be related to an acute bleeding
event or may be in the context of chronic anemia.
Although we have attempted to account for the
additional prognostic impact of bleeding, anemia,
and baseline hematocrit through a separate analyses
of studies that have adjusted for these covariates and
have shown that receipt of a blood transfusion is
consistently associated with an increased risk of
mortality, it is likely that the patients who receive a
blood transfusion are sicker and more hemodynami-
cally compromised, hence unmeasured confounders
may contribute to the adverse outcomes recorded.
Whereas studies in this meta-analysis have attempted
to adjust for confounders through adjustment of
baseline covariates and procedural demographics,
hematocrit, anemia, and bleeding events, they have
not compared the outcomes of patients with in-
dications for blood transfusions and have not been
transfused to those who have received a blood
transfusion, hence confounding by indication re-
mains a signiﬁcant limitation.
Finally, we found a high degree of statistical het-
erogeneity in several of our analyses, partly due to the
heterogeneous nature of the cohorts analyzed, as well
as the presence of large studies that have narrow
conﬁdence intervals, and their risk estimates do not
overlap with other studies. Whereas statistical het-
erogeneity is a limitation in some of our analyses,
the direction of the risk estimates of individual studies
consistently suggests increased harm among patients
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445who receive blood transfusions, and the heterogene-
ity observed may partly reﬂect differences in the
magnitude of the harm associated with transfusion.
CONCLUSIONS
Our meta-analysis of 19 studies including more than
2 million patients with more than 54,000 transfusion
events has shown that the prevalence of blood
transfusions in contemporary PCI is signiﬁcant with a
reported prevalence of 2.3% and is independently
associated with an increased risk of mortality and
MACE. Clinicians should minimize the risk of peri-
procedural bleeding complications during PCI
through the use of bleeding-avoidance strategies
such as the use of anticoagulants associated withreduced bleeding risk (42) and use of the transradial
access site approach for PCI, particularly in patients
at high risk of bleeding complications (43). Clini-
cians should avoid the use of judicious blood
transfusions after PCI in the absence of signiﬁcant
or active bleeding complications. Our data support
the need for a larger deﬁnitive trial to deﬁne
optimal transfusion strategies in patients undergo-
ing PCI given the signiﬁcant variation in practices
reported.
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